keyword
MENU ▼
Read by QxMD icon Read
search

intragastric balloon

keyword
https://www.readbyqxmd.com/read/28707286/intragastric-balloon-treatment-for-obesity-review-of-recent-studies
#1
REVIEW
Chinara M Tate, Allan Geliebter
INTRODUCTION: The FDA recently approved three intragastric balloon (IGB) devices, ReShape, ORBERA™, and Obalon for treatment of obesity. Given the high cost, complication risk, and invasiveness of bariatric surgery, IGB treatment may present a safer and lower cost option for weight reduction. IGBs are generally placed in the stomach endoscopically for up to 6 months to reduce gastric capacity, enhance feelings of fullness, and induce weight loss. The mechanism of action likely involves stimulation of gastric mechanoreceptors triggering short-acting vagal signals to brain regions implicated in satiety...
July 13, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28695632/the-effect-of-mirtazapine-on-gastric-accommodation-gastric-sensitivity-to-distention-and-nutrient-tolerance-in-healthy-subjects
#2
F Carbone, T Vanuytsel, J Tack
BACKGROUND: Disturbances of gastric motor function of functional dyspepsia (FD) have been implicated in the pathogenesis of the symptoms, and hence, motility modifying agents are considered for its treatment. Mirtazapine was recently shown to improve symptoms and increase nutrient tolerance in FD patients with weight loss. We aim to evaluate the effect of mirtazapine on gastric sensorimotor function in healthy volunteers (HV). METHODS: Thirty-one HV underwent an intragastric pressure (IGP) and barostat measurements on separate days before and after 3 weeks of placebo or mirtazapine (15 mg)...
July 11, 2017: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/28695461/is-endoscopy-really-necessary-for-placing-intragastric-balloons
#3
Elisabeth M H Mathus-Vliegen
BACKGROUND: Gastric balloons for weight loss have historically been placed after a screening endoscopy. However, the utility and yield of these endoscopies has not been studied. Therefore, we wanted to evaluate the utility of screening endoscopy and to assess patients who had balloons placed without endoscopy. METHODS: Data was collected on two cohorts. Cohort 1 consisted of patients who had a screening endoscopy prior to or upon balloon placement. Cohort 2 consisted of patients who were followed after having a balloon placed under fluoroscopic guidance without endoscopy...
July 10, 2017: Obesity Surgery
https://www.readbyqxmd.com/read/28622478/novel-nonsurgical-endoscopic-approaches-for-the-treatment-of-obesity
#4
Ryan T Hurt, Thomas H Frazier, Manpreet S Mundi
Globally, obesity is a leading cause of preventable death and is associated with >60 comorbid medical conditions, including 10 types of cancer that are strongly associated with body mass index. There are a number of traditional obesity treatments-for example, lifestyle management (eg, decreased caloric intake and increased expenditure), pharmacotherapy, and bariatric surgery. Recently, endoscopic approaches have emerged as a viable alternative for weight loss. Endoscopically placed intragastric balloons were introduced in the early 1980s for the treatment of medically complicated obesity but, unfortunately, had high rates of complications, such as premature deflation leading to obstruction...
June 1, 2017: Nutrition in Clinical Practice
https://www.readbyqxmd.com/read/28611347/erratum-does-combining-liraglutide-with-intragastric-balloon-insertion-improve-sustained-weight-reduction
#5
(no author information available yet)
[This corrects the article DOI: 10.4103/1319-3767.203362.].
May 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28552239/gastric-perforation-by-intragastric-balloon-in-patient-with-nissen-fundoplication
#6
Antonio Ríos, Beatríz Febrero, José Manuel Rodríguez
No abstract text is available yet for this article.
May 25, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/28516757/gastric-perforation-caused-by-an-intragastric-balloon-endoscopic-findings
#7
In Kyung Yoo, Hoon Jai Chun, Yoon Tae Jeen
Intragastric balloon (IGB) insertion has been most frequently used in the West as an effective endoscopic treatment for morbid obesity, in practice. Recently, there is a growing number of cases requiring IGB deployment for obesity treatment in Korea. One of the reported complications of IGB use is gastric perforation. A 47-year-old woman was admitted to the hospital with mild symptoms, 7 weeks after having an IGB placed. Esophagogastroduodenoscopy was performed and gastric ulcer perforation was observed in the ulcer base, where food particles were impacted...
May 18, 2017: Clinical Endoscopy
https://www.readbyqxmd.com/read/28470006/efficacy-of-intragastric-balloon-on-weight-reduction-saudi-perspective
#8
Ebtissam Saleh Almeghaiseeb, Muhammad Farooq Ashraf, Reem Abdullah Alamro, Abdulaziz Omar Almasoud, Abdulrahman Ali Alrobayan
AIM: To evaluate the safety and efficacy of intragastric balloon (IGB) in weight reduction in obese patients referred to a tertiary hospital in the Kingdom of Saudi Arabia. METHODS: Three hundred and one consecutive obese individuals, who underwent IGB placement during January 2009 to May 2015, were analyzed. The subjects aged 18 to 60 years and had a minimum body mass index (BMI) of 27 kg/m(2). The IGB was placed under conscious sedation and kept for 6 mo. Anthropometric measurements were recorded during and after 6 mo of IGB removal...
April 16, 2017: World Journal of Clinical Cases
https://www.readbyqxmd.com/read/28451930/efficacy-of-intragastric-balloon-treatment-for-adolescent-obesity
#9
Ricardo José Fittipaldi-Fernandez, Marcella Rodrigues Guedes, Manoel P Galvao Neto, Márcia Regina Simas Torres Klein, Cristina Fajardo Diestel
BACKGROUND: Several studies conducted in adults suggest that intragastric balloon (IGB) is an effective and safe method for weight loss. Although the prevalence of obesity in adolescents has increased in recent years, the outcomes of IGB treatment in this age group are not known. The aim of this study was to evaluate the safety and efficacy of IGB treatment for weight loss in adolescents followed up for 6 months. METHODS: This is a retrospective longitudinal study including 27 adolescents (14-19 years; 23 female)...
April 27, 2017: Obesity Surgery
https://www.readbyqxmd.com/read/28446931/evaluation-of-the-results-of-treatment-of-morbid-obesity-by-the-endoscopic-intragastric-balloon-implantation-method
#10
Wojciech Żurawiński, Dariusz Sokołowski, Karolina Krupa-Kotara, Elżbieta Czech, Krystyn Sosada
INTRODUCTION: Overweight and obesity are ranked in the fifth place among the risk factors responsible for the greatest number of deaths in the world. AIM: To assess the effects of treatment of patients with morbid obesity using endoscopic intragastric balloon (IGB) implantation. MATERIAL AND METHODS: Two hundred and seventy-two patients with obesity were treated using endoscopic intragastric balloon implantation. Upon analysis of the inclusion and exclusion criteria, the study covered a group of 63 patients with morbid obesity...
2017: Wideochirurgia i Inne Techniki Mało Inwazyjne, Videosurgery and Other Miniinvasive Techniques
https://www.readbyqxmd.com/read/28441654/gastric-ulcer-hemorrhage-a-potential-life-threatening-complication-of-intragastric-balloon-treatment-of-obesity
#11
Aleksandra Mojkowska, Stefan Gazdzinski, Mariusz Fraczek, Mariusz Wyleżoł
BACKGROUND: Some morbidly obese patients do not qualify for bariatric surgery due to general health contraindications. Intragastric balloon treatment might be a therapeutic option in the above-mentioned cases. It can prime super-obese patients with end-stage disease for bariatric surgery. As a neoadjuvant therapy before surgery, it leads to a downstage of the disease by preliminary weight reduction, to an improvement in general health and, in summary, to a reduction of the perioperative risk...
2017: Obesity Facts
https://www.readbyqxmd.com/read/28440517/-efficacy-and-future-of-endoscopic-bariatric-surgery-in-the-treatment-of-obesity-and-metabolic-diseases
#12
Shangjia Huang, Junchang Zhang, Zhiyong Dong, Cunchuan Wang
The emerging endoscopic technologies are proved to be effective treatments for obesity in selected patients and to offer the potential advantages of reduced invasiveness, reversibility and repeatability. From the view of operation principle, endoscopic technologies can be classified as restrictive procedure, malabsorption procedure and endoscopic revision of gastric bypass. Restrictive procedures include intragastric balloon, aspiration therapy, endoscopic sleeve gastroplasty (ESG) and transoral gastroplasty...
April 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28421456/filling-the-void-a-review-of-intragastric-balloons-for-obesity
#13
REVIEW
Patrick Laing, Tuan Pham, Linda Jo Taylor, John Fang
Endoscopic bariatric therapies are predicted to become much more widely used in North America for obese patients who are not candidates for bariatric surgery. Of all the endoscopic bariatric therapies, intragastric balloons (IGBs) have the greatest amount of clinical experience and published data supporting their use. Three IGBs are FDA approved and are now commercially available in the USA (Orbera, ReShape Duo, and Obalon) with others likely soon to follow. They are generally indicated for patients whose BMI ranges from 30 to 40 mg/kg(2) and who have failed to lose weight with diet and exercise...
April 18, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28361843/does-combining-liraglutide-with-intragastric-balloon-insertion-improve-sustained-weight-reduction
#14
Mahmoud M Mosli, Moaiad Elyas
BACKGROUND/AIM: Intragastric balloon (IGB) is an effective and safe method of weight reduction. However, IGBs have been associated with a high rate of weight regain post removal. Accordingly, ways to improve sustained weight reduction including concomitant treatment with Glucagon-like peptide 1 (GLP-1) agonists have been proposed. This study aims to evaluate the effect of adding Liraglutide to IGB insertion on sustained weight reduction. PATIENTS AND METHODS: A retrospective analysis of all cases treated with IGB with or without Liraglutide was performed...
March 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28320520/national-survey-for-bariatric-procedures-in-adolescent-long-time-follow-up
#15
Roberto Luca Castellani, Mauro Toppino, Franco Favretti, Francesco Saverio Camoglio, Nicola Zampieri
INTRODUCTION: The role of bariatric surgery and its role in adolescent is still under discussion worldwide. The aim of this study is to report an Italian survey for bariatric procedures in adolescents and the outcome with a medium and long-term follow-up. MATERIALS AND METHODS: We retrospectively analyzed consecutive data added into the Italian register of the society for bariatric surgery(period 2000-2010). We evaluated all patients treated in a 10-year period with a mean follow-up of 3 years...
March 14, 2017: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/28294385/potential-excitatory-role-of-nitric-oxide-on-2-deoxy-d-glucose-induced-gastric-motility-in-rats
#16
A M Sevgili, Z D Balkanci, A Erdem
Previous studies have shown that 2-deoxy-d-glucose (2-DG) increases gastric motility via the vagus nerve, but the underlying mechanism remains elusive. Since nitric oxide (NO) is involved in gastric motility, a possible interplay between 2-DG and NO can be suggested. In the present study, Wistar rats (250-350 g) of both sexes were intravenously injected with 2-DG (200 mg·kg(-1) ), and the effects of the intravenous injection of the nitric oxide synthase (NOS) inhibitors; nitro-l-arginine methyl ester (l-NAME, 10 mg·kg(-1) ) and N(ω) -nitro-l-arginine (l-NNA, 10 mg·kg(-1) ) were investigated...
March 13, 2017: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/28292405/selected-endoscopic-gastric-devices-for-obesity
#17
REVIEW
Kartik Sampath, Richard I Rothstein
This article focuses on the stomach target devices that are currently in various stages of development. Approved intragastric balloons, devices targeting small bowel and aspiration techniques, are described in other contributions to this issue. Bariatric endoscopic devices targeting the stomach directly alter gastric physiology and promote weight loss by potentially changing functional gastric volume, gastric emptying, gastric wall compliance, neurohormonal signaling, and, thereby, satiety. Many stomach-targeting devices are on the horizon for clinical use, and further study will determine the safety and efficacy for clinical use...
April 2017: Gastrointestinal Endoscopy Clinics of North America
https://www.readbyqxmd.com/read/28292403/intragastric-balloons-in-clinical-practice
#18
REVIEW
Marianna Papademetriou, Violeta Popov
Cost-effective therapies to address the growing epidemic of obesity are a leading priority in modern medicine. Intragastric balloons (IGBs) are one such option, with increased effectiveness compared with pharmacotherapy and lifestyle and a lower rate of adverse events than bariatric surgery. IGBs are endoscopically placed or swallowed space-occupying devices in the stomach. Three IGB systems were approved in 2015 to 2016 by the Food and Drug Administration for use in the United States, with more devices nearing approval...
April 2017: Gastrointestinal Endoscopy Clinics of North America
https://www.readbyqxmd.com/read/28285471/the-influence-of-the-orbera-intragastric-balloon-filling-volumes-on-weight-loss-tolerability-and-adverse-events-a-systematic-review-and-meta-analysis
#19
Nitin Kumar, Fateh Bazerbachi, Tarun Rustagi, Thomas R McCarty, Christopher C Thompson, Manoel P Galvao Neto, Natan Zundel, Erik B Wilson, Christopher J Gostout, Barham K Abu Dayyeh
BACKGROUND: The Orbera intragastric balloon (IGB) has been approved by the US Food and Drug Administration for use in patients with a body mass index (BMI) between 30 and 40 kg/m(2) and is in wide use worldwide as a primary and bridge obesity management tool. The balloon filling volume (BFV) ranges between 400 and 700 mL of saline. Our objective was to determine whether there is an association between BFV and clinically relevant endpoints, namely weight loss outcomes, balloon tolerability, and adverse events...
March 12, 2017: Obesity Surgery
https://www.readbyqxmd.com/read/28270675/spontaneous-hyperinflation-of-an-intragastric-balloon-5-months-after-insertion
#20
Sindhu Barola, Abhishek Agnihotri, Angela Chang Chiu, Anthony N Kalloo, Vivek Kumbhari
No abstract text is available yet for this article.
March 2017: American Journal of Gastroenterology
keyword
keyword
33321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"